Pfizer and Genmab’s Tivdak wins full FDA approval for cervical cancer
Pfizer and Genmab’s Tivdak (tisotumab vedotin-tftv) has won full approval from the US Food and Drug Administration (FDA) to treat patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy. The full approval is …